Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference

Rhea-AI Summary

Lifecore Biomedical (NASDAQ: LFCR) will participate in the William Blair 46th Annual Growth Stock Conference in Chicago. The event runs from June 2-4, 2026 at the Loews Chicago Hotel.

CEO Paul Josephs and CFO Ryan Lake will attend and hold investor meetings.

News Market Reaction – LFCR

+8.97%

9 alerts

+8.97% Session close to close

+2.0% Peak in 32 min

$187.92M Market Cap

0.7x Rel. Volume

In the May 21 session, LFCR gained 8.97%, reflecting a notable positive market reaction. Argus tracked a peak move of +2.0% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +9.0% in the session following this news. A strong positive reaction aligns with pri...

Analysis

The stock moved +9.0% in the session following this news. A strong positive reaction aligns with prior instances where visibility events, such as the April biomanufacturing summit, coincided with gains of around 3–4%. Conference participation at the William Blair Growth Stock Conference adds investor access but does not change fundamentals like the recent Q1 2026 revenue decline and net loss. Investors would need to weigh this against existing leverage, registered resale overhang, and past mixed responses to routine corporate news.

Key Figures

Conference edition: 46th Annual Conference dates: June 2–4, 2026

2 metrics

Conference edition 46th Annual William Blair Growth Stock Conference

Conference dates June 2–4, 2026 William Blair 46th Annual Growth Stock Conference

Historical Context

5 past events · Latest: May 06 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 06	Q1 2026 earnings	Negative	-3.9%	Weak Q1 2026 revenue and continued net loss with reaffirmed guidance.
Apr 29	Earnings date notice	Neutral	+2.6%	Announcement of timing and webcast details for upcoming Q1 2026 results.
Apr 22	Inducement grant	Neutral	-5.9%	5,000-share RSU inducement grant to a new hire under Nasdaq Rule 5635(c)(4).
Apr 08	Conference participation	Positive	+3.2%	Participation in American Biomanufacturing Summit to highlight injectable CDMO services.
Mar 26	Inducement grant	Neutral	-5.4%	18,500-share RSU inducement grant for a new employee under Nasdaq Rule 5635(c)(4).

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has triggered mixed reactions: earnings and inducement grants have skewed negative, while event participation announcements have seen modest positive moves.

Recent Company History

Over the last few months, Lifecore has alternated between operational updates and corporate housekeeping. Q1 2026 results on May 6 showed revenue decline and a loss, with shares falling 3.88%. Two Nasdaq Rule 5635(c)(4) inducement grants in late March and late April saw declines of 5.93% and 5.43%. By contrast, an April biomanufacturing summit participation announcement on April 8 coincided with a 3.16% gain, suggesting conferences and visibility events have been received more favorably than dilution-related items.

Key Terms

contract development and manufacturing organization, cdmo

2 terms

contract development and manufacturing organization technical

"a fully integrated injectables contract development and manufacturing organization (“CDMO”)"

A contract development and manufacturing organization (CDMO) is a specialized service provider that helps other companies design, test, produce and package drugs or medical products on a hired basis. Think of it as an outsourced factory and R&D partner that lets a company scale production without building its own plants. Investors watch CDMO relationships because they affect a drug’s time-to-market, manufacturing costs, supply reliability and overall project risk, all of which influence future revenue and valuation.

cdmo technical

"a fully integrated injectables contract development and manufacturing organization (“CDMO”)"

A contract development and manufacturing organization (CDMO) is a company that provides specialized services to help develop and produce pharmaceutical products for other businesses. Think of it as a contract factory that takes a company's recipe and makes the product on their behalf. For investors, CDMOs are important because they support the growth of pharmaceutical companies and can be key partners in bringing new medicines to market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CHASKA, Minn., May 21, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the William Blair 46^th Annual Growth Stock Conference. The conference will take place June 2-4, 2026, in Chicago, IL.

Details regarding Lifecore’s participation are as follows:

• William Blair 46th Annual Growth Stock Conference
  Details: Lifecore management, including Paul Josephs, chief executive officer, and Ryan Lake, chief financial officer, will participate in investor meetings.
  Conference Dates: June 2-4, 2026
  Location: Loews Chicago Hotel, Chicago, IL
  
  

About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.

Contact Information:
Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
sdiaz@vidasp.com

Jennifer Arcure (Media)
917-603-0681
jarcure@vidasp.com

Lifecore Biomedical
Ryan D. Lake (CFO)
952-368-6244
ryan.lake@lifecore.com

FAQ

When will Lifecore Biomedical (NASDAQ: LFCR) attend the William Blair 46th Annual Growth Stock Conference?

Lifecore Biomedical will attend the William Blair 46th Annual Growth Stock Conference from June 2-4, 2026. According to Lifecore, the event takes place over three days in Chicago.

Where is the William Blair 46th Annual Growth Stock Conference featuring Lifecore Biomedical held?

The conference featuring Lifecore Biomedical will be held at the Loews Chicago Hotel in Chicago, IL. According to Lifecore, company management will participate in investor meetings at this venue.

Which Lifecore Biomedical executives will participate in the June 2026 William Blair conference?

Lifecore Biomedical’s CEO Paul Josephs and CFO Ryan Lake will participate in the conference. According to Lifecore, these executives will join investor meetings during the June 2-4, 2026 event.

What is Lifecore Biomedical’s role at the William Blair 46th Annual Growth Stock Conference?

Lifecore Biomedical management will participate in investor meetings during the conference. According to Lifecore, CEO Paul Josephs and CFO Ryan Lake will represent the company at the June 2-4, 2026 event in Chicago.

Why is Lifecore Biomedical (LFCR) attending the William Blair 46th Annual Growth Stock Conference?

Lifecore Biomedical is attending to meet with investors at the William Blair conference. According to Lifecore, senior management will hold investor meetings at the Loews Chicago Hotel from June 2-4, 2026.